1
|
Colombo M, Mondini P, Minenza E, Foglia C, Mosconi A, Molica C, Pistola L, Ludovini V, Radice P. Corrigendum: A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: a case report. Front Oncol 2023; 13:1306238. [PMID: 37936611 PMCID: PMC10627224 DOI: 10.3389/fonc.2023.1306238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 10/05/2023] [Indexed: 11/09/2023] Open
Abstract
[This corrects the article DOI: 10.3389/fonc.2023.1102184.].
Collapse
Affiliation(s)
- Mara Colombo
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Patrizia Mondini
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Elisa Minenza
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Claudia Foglia
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Annamaria Mosconi
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Carmen Molica
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Lorenza Pistola
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Vienna Ludovini
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Paolo Radice
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
2
|
Colombo M, Mondini P, Minenza E, Foglia C, Mosconi A, Molica C, Pistola L, Ludovini V, Radice P. A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: A case report. Front Oncol 2023; 13:1102184. [PMID: 37025588 PMCID: PMC10072264 DOI: 10.3389/fonc.2023.1102184] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Accepted: 02/27/2023] [Indexed: 04/08/2023] Open
Abstract
The widespread adoption of gene panel testing for cancer predisposition is leading to the identification of an increasing number of individuals with clinically relevant allelic variants in two or more genes. The potential combined effect of these variants on cancer risks is mostly unknown, posing a serious problem for genetic counseling in these individuals and their relatives, in whom the variants may segregate singly or in combination. We report a female patient who developed triple-negative high grade carcinoma in the right breast at the age of 36 years. The patient underwent bilateral mastectomy followed by combined immunotherapy and chemotherapy (IMpassion030 clinical trial). Two years later she developed a skin recurrence on the right anterior chest wall. Despite intensive treatment, the patient died at 40-year-old due to disease progression. Gene panel testing of patient's DNA revealed the presence of a protein truncating variant in ATM [c.1672G>T; p.(Gly558Ter)] and of a not previously reported variant in the BRCA1 exon 22 donor splice site [c.5406+6T>C], whose clinical significance was unknown. The analysis of patient's RNA revealed the up-regulation of two alternative BRCA1 mRNA isoforms derived from skipping of exon 22 and of exons 22-23. The corresponding predicted protein products, p.(Asp1778GlyfsTer27) and p.(Asp1778_His1822del) are both expected to affect the BRCA1 C Terminus (BRCT) domain. The two variants were observed to co-occur also in the proband's brother who, in addition, was heterozygous for a common variant (c.4837A>G) mapped to BRCA1 exon 16. This allowed to ascertain, by transcript-specific amplification, the lack of functional mRNA isoforms expressed by the c.5406+6T>C allele and provided evidence to classify the BRCA1 variant as pathogenic, according to the guidelines of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium. To our knowledge, excluding two cases detected following the screening of population specific recurrent variants, only one ATM/BRCA1 double heterozygote has been reported in the literature, being the case here described the one with the youngest age at cancer onset. The systematic collection of cases with pathogenic variants in more than one cancer predisposition gene is needed to verify if they deserve ad hoc counseling and clinical management.
Collapse
Affiliation(s)
- Mara Colombo
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Patrizia Mondini
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Elisa Minenza
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Claudia Foglia
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Annamaria Mosconi
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Carmen Molica
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Lorenza Pistola
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Vienna Ludovini
- Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy
| | - Paolo Radice
- Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
3
|
Foglietta J, Ludovini V, Bianconi F, Pistola L, Reda MS, Al-Refaie A, Tofanetti FR, Mosconi A, Minenza E, Anastasi P, Molica C, Stracci F, Roila F. Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study. Genes (Basel) 2020; 11:genes11080925. [PMID: 32806537 PMCID: PMC7464094 DOI: 10.3390/genes11080925] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 08/05/2020] [Accepted: 08/06/2020] [Indexed: 01/04/2023] Open
Abstract
Hereditary breast and ovarian cancers are mainly linked to variants in BRCA1/2 genes. Recently, data has shown that identification of BRCA variants has an immediate impact not only in cancer prevention but also in targeted therapeutic approaches. This prospective observational study characterized the overall germline BRCA variant and variant of uncertain significance (VUS) frequency and spectrum in individuals affected by breast (BC) or ovarian cancer (OC) and in healthy individuals at risk by sequencing the entire BRCA genes. Of the 363 probands analyzed, 50 (13.8%) were BRCA1/2 mutated, 28 (7.7%) at BRCA1 and 23 (6.3%) at BRCA2 gene. The variant c.5266dupC p.(Gln1756Profs) was the most frequent alteration, representing 21.4% of the BRCA1 variants and 12.0% of all variants identified. The variant c.6313delA p.(Ile2105Tyrfs) of BRCA2 was the most frequent alteration observed in 6 patients. Interestingly, two new variants were identified in BRCA2. In addition, 25 different VUS were identified; two were reported for the first time in BRCA1 and two in BRCA2. The number of triple-negative BCs was significantly higher in patients with the pathogenic BRCA1/2-variant (36.4%) than in BRCA1/2 VUS (16.0%) and BRCA1/2 wild-type patients (10.7%) (p < 0.001). Our study reveals that the overall frequency of BRCA germline variants in the selected high-risk Italian population is about 13.8%. We believe that our results could have significant implications for preventive strategies for unaffected BRCA-carriers and effective targeted treatments such as PARP inhibitors for patients with BC or OC.
Collapse
Affiliation(s)
| | - Vienna Ludovini
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
- Correspondence: ; Tel./Fax: +39-075-5783453
| | | | - Lorenza Pistola
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Maria Sole Reda
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Antonella Al-Refaie
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Francesca Romana Tofanetti
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Annamaria Mosconi
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Elisa Minenza
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Paola Anastasi
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Carmen Molica
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| | - Fabrizio Stracci
- Department of Experimental Medicine, Public Health Section, University of Perugia, 06129 Perugia, Italy;
| | - Fausto Roila
- Medical Oncology Division, S. Maria della Misericordia Hospital, 06132 Perugia, Italy; (L.P.); (M.S.R.); (A.A.-R.); (F.R.T.); (A.M.); (E.M.); (P.A.); (C.M.); (F.R.)
| |
Collapse
|
4
|
Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol 2015; 27:487-93. [PMID: 26681678 DOI: 10.1093/annonc/mdv608] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 12/09/2015] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Current evidence suggest that trabectedin is particularly effective in cells lacking functional homologous recombination repair mechanisms. A prospective phase II trial was designed to evaluate the activity of trabectedin in the treatment of recurrent ovarian cancer patients presenting BRCA mutation and/or BRCAness phenotype. PATIENTS AND METHODS A total of 100 patients with recurrent BRCA-mutated ovarian cancer and/or BRCAness phenotype (≥2 previous responses to platinum) were treated with trabectedin 1.3 mg/mq i.v. q 3 weeks. The activity of the drug with respect to BRCA mutational status and to a series of polymorphisms [single-nucleotide polymorphisms (SNPs)] involved in DNA gene repair was analyzed. RESULTS Ninety-four were evaluable for response; in the whole population, 4 complete and 33 partial responses were registered for an overall response rate (ORR) of 39.4. In the platinum-resistant (PR) and -sensitive (PS) population, an ORR of 31.2% and 47.8%, and an overall clinical benefit of 54.2% and 73.9%, respectively, were registered. In the whole series, the median progression-free survival (PFS) was 18 weeks and the median overall survival (OS) was 72 weeks; PS patients showed a more favorable PFS and OS compared with PR patients. BRCA gene mutational status was available in 69 patients. There was no difference in ORR, PFS and OS according to BRCA 1-2 status nor any association between SNPs of genes involved in DNA repair and NER machinery and response to trabectedin was reported. CONCLUSIONS Our data prospectively confirmed that the signature of 'repeated platinum sensitivity' identifies patients highly responsive to trabectedin. In this setting, the activity of trabectedin seems comparable to what could be obtained using platinum compounds and the drug may represent a valuable alternative option in patients who present contraindication to receive platinum. EUDRACT NUMBER 2011-001298-17.
Collapse
Affiliation(s)
- D Lorusso
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - G Scambia
- Department of Obstetrics and Gynecology, Catholic University of Rome
| | - S Pignata
- Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples
| | - R Sorio
- Department of Oncology, CRO Aviano, Aviano
| | - G Amadio
- Department of Obstetrics and Gynecology, Catholic University of Rome
| | - S Lepori
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - A Mosconi
- Medical Oncology Unit, University Hospital S. Maria della Misericordia, Perugia
| | - C Pisano
- Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples
| | - G Mangili
- Department of Obstetrics and Gynecology, San Raffaele Hospital, Milan
| | - G Maltese
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - R Sabbatini
- Department of Oncology Haematology and Respiratory Disease, AOU Policlinico di Modena, Modena
| | - G Artioli
- Medical Oncology Unit, Hospital of Mirano, Mirano
| | - T Gamucci
- Medical Oncology Unit, Hospital 'SS. Trinità', Sora
| | - M Di Napoli
- Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples
| | - E Capoluongo
- Department of Molecular Biology, Catholic University of Rome
| | - V Ludovini
- Molecular Biology Unit, University Hospital S. Maria della Misericordia, Perugia, Italy
| | - F Raspagliesi
- Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Milan
| | - G Ferrandina
- Department of Obstetrics and Gynecology, Catholic University of Rome
| |
Collapse
|
5
|
Piccirillo M, Scambia G, Lorusso D, De Giorgi U, Nicoletto M, Lauria R, Mosconi A, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Pisano C, Cecere S, Di Napoli M, Salutari V, Daniele G, Gallo C, Perrone F, Pignata S. MITO (Multicentre Italian Trials in Ovarian cancer) - CERV 2 trial: a randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv339.01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Lorusso D, Scambia G, Colombo N, Reed N, Pisano C, Lord R, Mangili G, Mosconi A, Raspagliesi F, Palazzo A, Ditto A, Salutari V, Conte C, Amadio G, Lambiase A, Bordignon C. Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | - Rosemary Lord
- Clatterbridge Cancer Centre, Bebington, United Kingdom
| | | | | | | | | | - Antonino Ditto
- Fondazione IRCCS National Cancer Institute, Milan, Italy
| | | | | | | | | | | |
Collapse
|
7
|
Mosconi A, Crino L, Ludovini V, Scambia G, Ferrandina G, Breda E, Sabbatini R, Caserta C, De Angelis V, Pignata S. Molecular prognostic and predictive markers in gynecologic cancers: The translational 1 (T-1) study of the Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) group. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Mosconi A, Ludovini V, Pistola L, Tofanetti FR, Mameli MG, Anastasi P, Porrozzi S, Cavaliere A, Cantelmi MG, Crino L. Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Gori S, Sidoni A, Colozza M, Ferri I, Cioccoloni C, Fenocchio D, Mosconi A, Anastasi P, De Angelis V, Crinò L. EGFR, MAPK, and Akt status by immunohistochemistry (IHC) are not correlated with clinical outcome in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) with or without chemotherapy (CT). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1090 Background: T alone or in combination with CT has been shown to be an active therapy in HER2-positive MBC pts. However, not all pts will benefit and mechanisms of resistance to T are still poorly understood. The aim of this study was to evaluate the IHC expression of EGFR and two downstream effectors of the EGFR family signaling pathway, MAPK and Akt and their correlation with clinical outcome in HER2-positive MBC pts treated with T ± CT. Methods: 133 consecutive HER2+ MBC pts were treated between 04/99 and 03/06 but tumor tissue was available for this analysis only from 45 pts. HER2 evaluated by CB11 was scored according to Herceptest. Tumors were considered EGFR positive if =1% positive tumor cells and MAPK positive and Akt positive if the percentage of positive tumor cells was =10%. Results: At median follow up of 57 months (range 5–229) from the start of T, 45 pts were evaluable for TTP and OS and 42 for response to T. Median age of pts was 53 years (23–77). Twenty seven objective responses (CR+PR) to T ± CT (64.28%) were observed; median TTP was 24 months (3.3–179.8). In 11 of the 27 responsive pts (40.7%), progression was observed in CNS ± other sites. Median OS from the start of T was 74 months. EGFR positive tumors were 10 (22.2%), MAPK positive tumors were 16 (35.5%) and Akt positive tumors were 23 (51.1%). We analyzed the correlation of HER2, EGFR, MAPK and Akt status with response to T, TTP and OS. HER2 was significantly correlated with response to T (p = 0.013): in HER2 3+ tumors we observed 22 (9 CR and 13 PR) out of 27 objective responses but, no significant correlation was found between HER2 status and TTP and OS. EGFR, MAPK and Akt status of tumor were not significantly associated with response to T, TTP and OS in this series of HER2+ MBC pts. Conclusions: We did not found any significant correlation between EGFR, MAPK, Akt status evaluated by IHC and clinical outcome in HER2+ MBC pts treated with T ± CT. Only HER2 status evaluated by IHC significantly correlated with response to T ± CT. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Gori
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - A. Sidoni
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - M. Colozza
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - I. Ferri
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - C. Cioccoloni
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - D. Fenocchio
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - A. Mosconi
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - P. Anastasi
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - V. De Angelis
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| | - L. Crinò
- Azienda Ospedaliera, Perugia, Italy; University, Perugia, Italy
| |
Collapse
|
10
|
Ludovini V, Gori S, Mosconi A, Pistola L, Rulli E, Rulli A, Anastasi P, Pacifico E, Sidoni A, Tofanetti FR, Colozza M. Evaluation of HER-2 in serum and tissue: correlation with clinical-pathological parameters and outcome in early stage breast cancer (BC) patients (pts). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20066 Background: HER2 is amplified and/or overexpressed in approximately 20–30% of invasive BC and is associated with poor prognosis. It is also a predictive marker of response to trastuzumab. The extracellular domain of the HER2 protein (sHER2) is frequently cleaved and released into the circulation where it can be detected by ELISA in up to 45% of advanced BC. We evaluated HER2 expression in paired serum and tissue samples of operable BC pts to analyze 1) the correlation between sHER2 and HER2 tumor status 2) their relationship with clinical-pathological parameters and 3) their impact on the outcome. Methods: 188 consecutive stage I-III BC pts were included in this study from May 2000 to July 2005. sHER2 was measured by ELISA (manual Kit “Oncogene Science Diagnostics” and automated version “ADVIA Centaur”) before the local treatment. Tumor tissue was analyzed by IHC with CB11 antibody and scored with Dako Hercept-test. HER2 amplification was determined using the Ventana FISH assay in patients with 2+ by IHC. Chi-squared test was used to evaluate the association between HER2 and patients’ clinical-pathological features. Survival outcomes were analyzed using Cox’s model. Results: Median age was 56.6 years; 122 pts received adjuvant chemotherapy, 54 endocrine therapy and 83 both. Forty-three pts (23%) had HER2 overexpression/amplification in tumor tissue and 25 pts (13%) had sHER2 levels ≥15 ng/ml (cut-off level) with a concordance of 85%. Both high sHER2 levels and HER2 tumor expression were associated with high histological grade (p = .02 and p < .0001 respectively) and negativity of ER (p = .0035 and p < .0001) and PgR (p = .0056 and p =. 002). At a median follow-up of 2.4 years we observed 8 deaths and 19 relapses. At univariate analysis high sHER2 levels (evaluated as continuous variable) were significantly correlated with shorter DFS (p = 0.0002) even if at multivariate analysis high sHER2 levels, after adjustment for stage and ER status, were associated with a shorter DFS with borderline significance (p = 0.06). Conclusion: Our preliminary data indicate that the evaluation of sHER2 at diagnosis defines a small subgroup of early BC pts with a poor prognosis even if it needs to be confirmed in a longer follow up. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Ludovini
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - S. Gori
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - A. Mosconi
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - L. Pistola
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - E. Rulli
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - A. Rulli
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - P. Anastasi
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - E. Pacifico
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - A. Sidoni
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - F. R. Tofanetti
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| | - M. Colozza
- Medical Oncology Azienda Ospedaliera, Perugia, Italy; Istituto Mario Negri, Milano, Italy; Breast Unit Azienda Ospedaliera, Perugia, Italy; Laboratorio Analisi Azienda Ospedaliera, Perugia, Italy; Pathology Department Azienda Ospedaliera, Perugia, Italy
| |
Collapse
|
11
|
Cocconi G, Bisagni G, Bella M, Acito L, Anastasi P, Carpi A, Di Costanzo F, Frassoldati A, Mosconi A, Borrini A, Buzzi P. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study. Am J Clin Oncol 1999; 22:593-600. [PMID: 10597744 DOI: 10.1097/00000421-199912000-00010] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The Italian Oncology Group for Clinical Research tested two experimental chemotherapy strategies in an attempt to improve the results achievable with conventional chemotherapy in metastatic breast cancer. One hundred sixty-two patients were randomly allocated as follows: (a) to the conventional cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy regimen (CMF); (b) to a rotational crossing program (ROT-CROSS); or (c) to a sequential intensification program (SEQ-INT). The same single agents (C, M, F, cisplatin, etoposide, and doxorubicin) were administered in both experimental arms, but following a different policy. The SEQ-INT program induced a significantly higher complete response (32% vs. 6%, p = 0.0006) and objective response rate (72% vs. 42%, p = 0.0047) than CMF did. There were no differences in survival between CMF and either experimental arm. A number of side effects were significantly more with both experimental chemotherapies than with CMF, but the treatments were generally tolerable. Although some caution is required when interpreting a significant advantage found between an entire chemotherapeutic strategy and a single conventional combination, this study documents the potential therapeutic advantage of administering different sequential chemotherapies, and changing each at the time of maximum result without waiting for a progression. The impressive cytoreductive effects achievable with this policy (SEQ-INT) in metastatic disease merit further investigation in the adjuvant setting.
Collapse
Affiliation(s)
- G Cocconi
- Medical Oncology Institutions of Parma, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Psychological distress in parents of children with acute lymphatic leukemia was evaluated by means of the Symptom Distress Checklist. This scale was administered twice: within a few days after the child's admission to hospital and 8 months later. Twenty-five consecutive, unselected subjects were compared with controls matched for age, sex, marital status and social class. At the first evaluation the sample presented higher mean scores than the controls for anxiety (P less than 0.005), depression (P less than 0.005), sleep disturbances (P less than 0.005) and obsessions (P less than 0.05). An 8 months' follow-up confirmed the persistence of anxiety (P less than 0.05), sleep disturbances (P less than 0.05) and above all depression (P less than 0.005).
Collapse
|
13
|
Magni G, Messina C, De Leo D, Mosconi A, Carli M. [Psychological distress among parents of children with acute lymphatic leukemia. 1st follow-up]. Minerva Psichiatr 1983; 24:43-6. [PMID: 6581374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|